Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0476089 (
endometrial cancer
)
11,379
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
BHLHE40
and BHLHE41 (
BHLHE40
/41) are basic helix-loop-helix type transcription factors that play key roles in multiple cell behaviors.
BHLHE40
/41 were recently shown to be involved in an epithelial-to-mesenchymal transition (EMT). However, the precise mechanism of EMT control by
BHLHE40
/41 remains unclear. In the present study, we demonstrated that
BHLHE40
/41 expression was controlled in a pathological stage-dependent manner in human
endometrial cancer
(HEC). Our in vitro assays showed that
BHLHE40
/41 suppressed tumor cell invasion.
BHLHE40
/41 also suppressed the transcription of the EMT effectors SNAI1, SNAI2, and TWIST1. We identified the critical promoter regions of TWIST1 for its basal transcriptional activity. We elucidated that the transcription factor SP1 was involved in the basal transcriptional activity of TWIST1 and that
BHLHE40
/41 competed with SP1 for DNA binding to regulate gene transcription. This study is the first to report the detailed functions of
BHLHE40
and BHLHE41 in the suppression of EMT effectors in vitro. Our results suggest that
BHLHE40
/41 suppress tumor cell invasion by inhibiting EMT in tumor cells. We propose that
BHLHE40
/41 are promising markers to predict the aggressiveness of each HEC case and that molecular targeting strategies involving
BHLHE40
/41 and SP1 may effectively regulate HEC progression.
...
PMID:Regulation of the Mechanism of TWIST1 Transcription by BHLHE40 and BHLHE41 in Cancer Cells. 2639 53
BHLHE40
and BHLHE41 (
BHLHE40
/41) are basic helix-loop-helix type transcription factors involved in multiple cell activities including epithelial-to-mesenchymal transition (EMT). However, the expression mechanism of
BHLHE40
/41 in EMT remains unclear. In the present study, we showed that the expression levels of
BHLHE40
/41 were negatively correlated with those of the microRNA (MIR) 130 family in
endometrial cancer
(EC) specimens. Our
in vitro
assays indicated that the expression of
BHLHE40
/41 was suppressed directly by the MIR130 family in a 3'-untranslated region-mediated manner. In EC cells, the MIR130 family promoted EMT and tumor cell invasion by suppressing the expression of
BHLHE40
/41. We identified the critical promoter region of the
MIR301B
-
MIR130B
cluster for its basal transcription by the transcription factor, SP1. We also found that
BHLHE40
/41 suppressed the expression of MIR301B and MIR130B, and we identified a binding site in the promoter region for
BHLHE40
/41. This study is the first to report that
BHLHE40
/41 and the MIR301B-MIR130B cluster suppressed each other to regulate EMT and invasion of EC cells. We propose that
BHLHE40
/41 and the MIR130 family are excellent markers to predict the progression of EC cases, and that molecular therapy targeting the MIR130 family-
BHLHE40
/41 axis may effectively control EC extension.
...
PMID:Mutual suppression between BHLHE40/BHLHE41 and the MIR301B-MIR130B cluster is involved in epithelial-to-mesenchymal transition of endometrial cancer cells. 3138 92